GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (OTCPK:SGBI) » Definitions » Shiller PE Ratio

Sangui Biotech International (Sangui Biotech International) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to . Start your Free Trial

What is Sangui Biotech International Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sangui Biotech International Shiller PE Ratio Historical Data

The historical data trend for Sangui Biotech International's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Shiller PE Ratio Chart

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sangui Biotech International's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Shiller PE Ratio falls into.



Sangui Biotech International Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sangui Biotech International's E10 for the quarter that ended in Mar. 2023 is calculated as:

For example, Sangui Biotech International's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0/122.4024*122.4024
=0.000

Current CPI (Mar. 2023) = 122.4024.

Sangui Biotech International Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 -0.010 98.516 -0.012
201309 0.000 98.983 0.000
201312 0.000 99.356 0.000
201403 -0.010 99.543 -0.012
201406 -0.010 99.543 -0.012
201409 -0.001 99.823 -0.001
201412 -0.001 99.543 -0.001
201503 -0.001 99.717 -0.001
201506 -0.006 100.417 -0.007
201509 -0.001 100.417 -0.001
201512 -0.001 99.717 -0.001
201603 -0.001 100.017 -0.001
201606 0.000 100.717 0.000
201609 0.000 101.017 0.000
201612 -0.001 101.217 -0.001
201703 0.000 101.417 0.000
201706 0.000 102.117 0.000
201709 0.000 102.717 0.000
201712 0.000 102.617 0.000
201803 0.000 102.917 0.000
201806 0.000 104.017 0.000
201809 0.000 104.718 0.000
201812 0.000 104.217 0.000
201903 0.000 104.217 0.000
201906 -0.001 105.718 -0.001
201909 0.000 106.018 0.000
201912 0.000 105.818 0.000
202003 0.000 105.718 0.000
202006 0.000 106.618 0.000
202009 0.000 105.818 0.000
202012 0.000 105.518 0.000
202103 0.000 107.518 0.000
202106 0.000 108.486 0.000
202109 0.000 109.435 0.000
202112 0.000 110.384 0.000
202203 0.000 113.968 0.000
202206 0.000 115.760 0.000
202209 0.000 118.818 0.000
202212 0.000 119.345 0.000
202303 0.000 122.402 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sangui Biotech International  (OTCPK:SGBI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sangui Biotech International Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (Sangui Biotech International) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Executives
Hubertus Schmelz director NEUER WALL 54, HAMBURG 2M D-20354
Joachim Fleing director ALFRED HERRHAUSENSTR 44, WITTEN 2M 58455
Thomas Striepe director NEUER WALL 54, HAMBURG 2M D-20354
Wolfgang Barnikol director ALFRED HERRHAUSEN STR 44, WITTEN 2M 58455
Lutz Joachim director ALFRED-HERRHAUSEN-ST. 44, WITTEN 2M 58455
Christoph Ludz director SANDERSKOPPEL 17, HAMBURG 2M 22391

Sangui Biotech International (Sangui Biotech International) Headlines

No Headlines